The abstract is read at the publisher; the summary is JClub's.
High-dose, short-term intravenous methylprednisolone in ethambutol-induced optic neuropathy is linked to more BCVA responders at 6 months (72.0% vs 46.0%).
- Why it matters: EtON can cause irreversible visual impairment and has no established treatment beyond stopping ethambutol, leaving clinicians uncertain whether corticosteroids help.
- What they did: In a double-blind randomized placebo-controlled trial at a tertiary care center in India, 100 patients received IVMP 1 gram daily for 5 days or placebo plus standard care, with BCVA assessed at 6 months.
- The result: At 6 months, 36/50 IVMP patients improved by two or more lines in BCVA versus 23/50 with placebo (p=0.008), with visual field gains (MD and VFI) and no serious treatment-related adverse events.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.